📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
Chinese Hamster Ovary Cells – A Biologics Powerhouse (past, present & future?)
The first FDA approved recombinant protein therapeutic developed in 1982 was insulin, developed by Genentech/Eli…
Blog
Type 2 diabetes and obesity: Twincretins and the potential of dual GLP-1/GIP agonists
The combination of GLP-1 and GIP agonists, dubbed ‘twincretins’, has received much attention…
Blog
Stoptober: Prevention is better than cure
Allan Jordan, Sygnature’s VP of oncology drug discovery, explains why campaigns…
Journal Papers
Novel variants provide differential stabilisation of human equilibrative nucleoside transporter 1 states
Jessica C Boakes, Steven P D Harborne, Jessie T S Ngo, Christos Pliotas, Adrian Goldman Abstract Human equilibrative nucleoside…
Blog
Type 2 diabetes: despite so many treatment options is diabetes drug discovery addressing unmet needs?
The World Health Organisation estimates that approximately 422 million people worldwide have diabetes. Type 2…
Journal Papers
Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation
Andrew Novak, David Laughton, Rebecca Lane, Emma Blackham, Jennifer Thomas, Elli Chatzopoulou, Joseph Wrigglesworth, Abdul…
Blog
CellCentric & Sygnature Discovery: Success with Inobrodib – First-in-Class Oral Anti-Cancer Drug
Inobrodib, an exciting, new, first-in-class oral anti-cancer drug in clinical development by CellCentric,…
Blog
Step Pharma and Sygnature Discovery enter clinical development with novel first-in-class compound for treatment of relapsed/refractory B or T cell lymphoma patients
The journey of a drug discovery project, from its scientific inception to clinical…
News
Sygnature Discovery partners the Oncology Development Programme (ODP2) to find UK-based breakthroughs in Oncology
Sygnature Discovery joins four of the top ten global pharma companies,…
News
Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities
Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB…
News
New platform set to accelerate early-stage targeted protein degradation
Sygnature Discovery, the global integrated drug discovery company, has unveiled a new platform that facilitates…
Blog
Have you considered a PROTAC approach?
Recently, there has been a great deal of interest in the potential of PROTACs…
Blog
Protein Binders to Degraders: Navigating the Route – Sygnature Discovery
Developing orally bioavailable degraders with CHARMED. De-risk the challenges and speed up early proof of concept.
Journal Papers
CTP Synthase 1 Is a Novel Therapeutic Target in Lymphoma
Hélène Asnagli, Norbert Minet, Christina Pfeiffer, Eef Hoeben, Rebecca Lane, David Laughton, Louise Birch, Geraint Jones, Andrew Novak, Andrew E Parker, Heinz Ludwig, Alain Fischer, Sylvain Latour, Philip…
Blog
Shaping the Future of Lung Cancer Treatment
The 12th of April is a landmark day each year for our VP of Oncology…
News
Sygnature Discovery and Daewoong Pharma announce research collaboration
Sygnature Discovery is pleased to have entered into a research collaboration agreement with the global…
Blog
Bifunctional Degrader Drug Discovery: The Power of measuring EPSA
Learn from Dr Phillip MacFaul, Sygnature Discovery's Principal Scientist in DMPK about measuring EPSA in bifunctional degraders.
Journal Papers
Pharmacokinetics of N,N-dimethyltryptamine in Humans
Meghan Good, Zelah Joel, Tiffanie Benway, Carol Routledge, Chris Timmermann, David Erritzoe, Richard Weaver, Graham Allen, Charlotte Hughes, Helen Topping, Amy Bowman, Ellen James Abstract Background…
Blog
Neuroplasticity and Neuroinflammation at AD/PD 2023: Sygnature Discovery Insights
The AD/PD conference is a leading international forum for research in Alzheimer's and Parkinson's diseases. Dr Max Mirza shares his thoughts.
Blog
De-risking Projects with Form Analysis: Pre-clinical Tox Insights
Dr David Pearson, Director of Form and Formulation notes how correct form analysis can improve projects and reflects on a year of the department.
Blog
In Vitro to In Vivo Translation in Lead Optimization: Bridging the Biology Gap
A generic in vitro/in vivo translational journey   Drug discovery is a complex…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch